What is a stock summary page? Click here for an overview.
Business Description

Lobe Sciences Ltd
NAICS : 541714
SIC : 3741
ISIN : CA53946V2066
Description
Lobe Sciences Ltd is a biopharmaceutical company committed to discovering and developing patient-focused medicines for orphan and rare diseases. It is engaged in drug research and development to improve brain and mental health and wellness. The company plans to commercialize a medical food named Altemia for the treatment of Sickle Cell Disease and has other drugs in pipeline such as L-130 Treatment for Chronic Cluster Headache, L-131 Treatment for Pediatric Anxiety and S-100 Treatment for Sickle Cell Disease.
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.01 | |||||
Equity-to-Asset | -57.63 | |||||
Debt-to-Equity | -0.55 | |||||
Debt-to-EBITDA | -0.45 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 44.1 | |||||
3-Year FCF Growth Rate | 70.4 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 48.19 | |||||
9-Day RSI | 50.56 | |||||
14-Day RSI | 51.84 | |||||
3-1 Month Momentum % | 29.41 | |||||
6-1 Month Momentum % | 37.5 | |||||
12-1 Month Momentum % | 83.33 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.03 | |||||
Quick Ratio | 0.03 | |||||
Cash Ratio | 0.01 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -66.1 | |||||
Shareholder Yield % | -26.1 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
FCF Margin % | -443 | |||||
ROA % | -353.63 | |||||
ROIC % | -121.27 | |||||
3-Year ROIIC % | -151.4 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 23 | |||||
EV-to-EBIT | -1.5 | |||||
EV-to-EBITDA | -1.52 | |||||
EV-to-Revenue | 47.51 | |||||
EV-to-FCF | -10.97 | |||||
Earnings Yield (Greenblatt) % | -66.67 | |||||
FCF Yield % | -14.08 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:LOBEF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lobe Sciences Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.1 | ||
EPS (TTM) ($) | -0.024 | ||
Beta | -0.04 | ||
3-Year Sharpe Ratio | -0.44 | ||
3-Year Sortino Ratio | -0.62 | ||
Volatility % | 43.88 | ||
14-Day RSI | 51.84 | ||
14-Day ATR ($) | 0.005772 | ||
20-Day SMA ($) | 0.023135 | ||
12-1 Month Momentum % | 83.33 | ||
52-Week Range ($) | 0.0082 - 0.0305 | ||
Shares Outstanding (Mil) | 192.65 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Lobe Sciences Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Lobe Sciences Ltd Stock Events
Event | Date | Price ($) | ||
---|---|---|---|---|
No Event Data |
Lobe Sciences Ltd Frequently Asked Questions
What is Lobe Sciences Ltd(LOBEF)'s stock price today?
The current price of LOBEF is $0.02. The 52 week high of LOBEF is $0.03 and 52 week low is $0.01.
When is next earnings date of Lobe Sciences Ltd(LOBEF)?
The next earnings date of Lobe Sciences Ltd(LOBEF) is 2025-04-29 Est..
Does Lobe Sciences Ltd(LOBEF) pay dividends? If so, how much?
Lobe Sciences Ltd(LOBEF) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |